Ovarian Cancer Clinical Trial

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Summary

The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Female patients with histologically diagnosed serous ovarian cancer or recurrent serous ovarian cancer.
Patients must have completed at least 2 previous courses of platinum containing therapy; the patient must have been platinum sensitive to the penultimate chemo regimen.
For the last chemotherapy course prior to enrolment on the study, patients must have demonstrated an objective stable maintained response (partial or complete response) and this response needs to be maintained until completion of chemotherapy.
Patients must be treated on the study within 8 wks of completion of their final dose of the platinum containing regimen.

Exclusion Criteria:

Previous treatment with PARP inhibitors including AZD2281
Patients with low grade ovarian carcinoma.
Patients who have had drainage of their ascites during the final 2 cycles of their last chemotherapy regimen prior to enrolment on the study
Patients receiving any chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study entry (or a longer period depending on the defined characteristics of the agents used).

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

265

Study ID:

NCT00753545

Recruitment Status:

Active, not recruiting

Sponsor:

AstraZeneca

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 70 Locations for this study

See Locations Near You

Research Site
Berkeley California, 94704, United States
Research Site
Indianapolis Indiana, 46202, United States
Research Site
Boston Massachusetts, 02114, United States
Research Site
Boston Massachusetts, 02215, United States
Research Site
Providence Rhode Island, 02905, United States
Research Site
East Bentleigh , 3165, Australia
Research Site
Melbourne , 3000, Australia
Research Site
Randwick , 2031, Australia
Research Site
Innsbruck , 6020, Austria
Research Site
Wein , 1130, Austria
Research Site
Wien , 1090, Austria
Research Site
Brussels , 1090, Belgium
Research Site
Leuven , 3000, Belgium
Research Site
Vancouver British Columbia, V5Z 4, Canada
Research Site
Toronto Ontario, M5G 2, Canada
Research Site
Sherbrooke Quebec, J1H 5, Canada
Research Site
Quebec , G1R 2, Canada
Research Site
Brno , 656 5, Czechia
Research Site
Olomouc , 775 2, Czechia
Research Site
Praha 10 , 100 3, Czechia
Research Site
Tartu , 51014, Estonia
Research Site
Bordeaux , 33076, France
Research Site
Caen Cedex , 14076, France
Research Site
Lyon Cedex 08 , 69373, France
Research Site
Nantes , 44202, France
Research Site
Essen , 45147, Germany
Research Site
Freiburg , 79106, Germany
Research Site
Göttingen , 37075, Germany
Research Site
Hannover , 30177, Germany
Research Site
Kiel , 24105, Germany
Research Site
Marburg , 35043, Germany
Research Site
München , 81675, Germany
Research Site
Ulm , 89081, Germany
Research Site
Wiesbaden , 65199, Germany
Research Site
Jerusalem , 91031, Israel
Research Site
Jerusalem , 91120, Israel
Research Site
Ramat Gan , 52621, Israel
Research Site
Tel-Aviv , 64239, Israel
Research Site
Zerifin , 70300, Israel
Research Site
Amsterdam , 1066 , Netherlands
Research Site
Amsterdam , 1081 , Netherlands
Research Site
Grzepnica , 72-00, Poland
Research Site
Poznan , 60-56, Poland
Research Site
Poznan , 61-86, Poland
Research Site
Poznań , , Poland
Research Site
Warszawa , 02-78, Poland
Research Site
Cluj-Napoca , 40001, Romania
Research Site
Iasi , 70010, Romania
Research Site
Suceava , 72023, Romania
Research Site
Barnaul , 65604, Russian Federation
Research Site
Ekaterinburg , 62003, Russian Federation
Research Site
Obninsk , 24903, Russian Federation
Research Site
Orenburg , 46002, Russian Federation
Research Site
Perm , 61406, Russian Federation
Research Site
Pyatigorsk , 35750, Russian Federation
Research Site
Saint-Petersburg , 19775, Russian Federation
Research Site
St. Petersburg , 19700, Russian Federation
Research Site
Voronezh , 39400, Russian Federation
Research Site
Córdoba , 14004, Spain
Research Site
Madrid , 08035, Spain
Research Site
Madrid , 28007, Spain
Research Site
Madrid , 28041, Spain
Research Site
Valencia , 46010, Spain
Research Site
Donetsk , 83092, Ukraine
Research Site
Kyiv , 03115, Ukraine
Research Site
Ternopil , 46023, Ukraine
Research Site
Uzhhorod , 88014, Ukraine
Research Site
Edinburgh , EH4 2, United Kingdom
Research Site
London , SW17 , United Kingdom
Research Site
London , SW3 6, United Kingdom
Research Site
Manchester , M20 4, United Kingdom
Research Site
Sutton , SM2 5, United Kingdom
Research Site
Wirral , CH63 , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

265

Study ID:

NCT00753545

Recruitment Status:

Active, not recruiting

Sponsor:


AstraZeneca

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.